GlpBio

Pirinixil (BR-931)

目录号: GC31488纯度: >98%同义词: 匹立昔尔; BR-931
COASDSData Sheet
Pirinixil (BR-931) 是一种低毒的降血脂药。
Pirinixil (BR-931)
Cas No.: 65089-17-0
规格价格库存数量操作
1mg¥8,381.00现货
1
5mg¥13,405.00现货
1
10mg¥21,456.00现货
1
电话: 400-920-5774Email: sales@glpbio.cn

文献被引

本产品暂无引用记录;以下为 GlpBio 产品在 Nature / Cell / Science 等顶刊的客户引用样例
  • Nature cover
    Nature
    641, 529–536 (2025)
  • Nature cover
    Nature
    628, 630–638 (2024)
  • Nature cover
    Nature
    632, 686–694 (2024)
  • Nature cover
    Nature
    618, 1017–1023 (2023)
  • Nature cover
    Nature
    610, 366–372 (2022)
  • Cell cover
    Cell
    187(9):2288-2304 (2024)
  • Cell cover
    Cell
    183(7):1867-1883 (2020)
  • Science cover
    Science
    388(6745) (2025)
  • Science cover
    Science
    387(6739) (2025)
  • Science cover
    Science
    387(6734) (2025)
  • Cell Research cover
    Cell Research
    35, 97–116 (2025)
  • Cell Research cover
    Cell Research
    34, 683–706 (2024)
  • Cell Research cover
    Cell Research
    33, 273–287 (2023)
  • Cell Research cover
    Cell Research
    33, 546–561 (2023)
  • Cell Research cover
    Cell Research
    33, 904–922 (2023)
  • Cell Research cover
    Cell Research
    31, 1291–1307 (2021)

产品描述 Description

Pirinixil is a hypolipidemic agent of low toxicity.

Pirinixil is a hypolipidemic agent of low toxicity. Total cholesterol is reduced by Pirinixi in the spleen, kidney and heart of rats. Pirinixil decreases the estimated total body cholesterol approximately 40%[1]. Pirinixil increases plasma cholesterol levels significantly without affecting plasma triglycerides. Liver cholesterol and triglycerides are markedly reduced by Pirinixil, while combined plasma and liver lipid levels decrease approximately 20%. Liver HMG-CoA reductase activity is not affected, but cholesterol 7α-hydroxylase is significantly reduced by Pirinixil[2].

[1]. D'Atri G, et al. Clofibrate, pirinixil (BR 931) and WY-14,643 do not affect body cholesterol in Sprague-Dawley rats. Atherosclerosis. 1980 Nov;37(3):475-83. [2]. Kritchevsky D, et al. Increased plasma cholesterol and decreased body lipid levels in Wistar rats following pirinixil(BR 931) treatment. Pharmacol Res Commun. 1979 Jun;11(6):475-82.

实验参考方法 Experimental Reference Method

Animal experiment:

Male Sprague-Dawley rats, weighing 220 to 230 g at the start of each experiment, are used in all studies. They are kept in an air-conditioned environment, with controlled lighting and free access to water. Dietary treatments are (A) standard diet for rats and (B) 2% cholesterol+2% cholic acid regimen. Both diets are administered ad libitum, respectively for 1 and 2 weeks (standard diet) and for 2 weeks (cholesterolcholic acid diet). Groups of 5 rats in each of the 3 experiments (1 and 2 weeks with the standard diet, 2 weeks with the cholesterol-cholic acid diet) are administered Pirinixil daily in carboxymethylcellulose vehicle by gastric intubation, at the doses of 20 mg/kg. Controls are given a similar volume of vehicle daily by intubation[1].

References:

[1]. D'Atri G, et al. Clofibrate, pirinixil (BR 931) and WY-14,643 do not affect body cholesterol in Sprague-Dawley rats. Atherosclerosis. 1980 Nov;37(3):475-83.
[2]. Kritchevsky D, et al. Increased plasma cholesterol and decreased body lipid levels in Wistar rats following pirinixil(BR 931) treatment. Pharmacol Res Commun. 1979 Jun;11(6):475-82.

产品文档 Product Documents

Purity:>98%
COASDSData Sheet

化学性质Chemical Properties

CAS 号
65089-17-0
同义词
匹立昔尔; BR-931
SMILES
O=C(NCCO)CSC1=NC(NC2=CC=CC(C)=C2C)=CC(Cl)=N1
分子式
C16H19ClN4O2S
分子量
366.87 g/mol
溶解性
Soluble in DMSO
保存条件
Store at -20°C
General tips
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
为了提高溶解度，请将管子加热至 37°C，然后在超声波浴中震荡一段时间。
Shipping Condition
评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备 RT，或根据请求配备蓝冰。

计算工具摩尔浓度 / 稀释 / 分子量 / 单位换算 / 体内配方 / 溶解度

g/mol